Physician profile
Kristopher Jon-Amor Patnugot
NPI 1649614470
$5,773.93
in general payments reported to CMS, 2019-2025
24 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $384 · 2021: $720 · 2022: $985 · 2023: $990 · 2024: $1,212 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,398.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,641.07 | 2021-2025 | |
| Orexo US, INC. | $1,028.54 | 2019-2025 | Zubsolv |
| Indivior INC. | $486.17 | 2019-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $363.11 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $357.20 | 2022-2025 | Caplyta |
| Lundbeck LLC | $346.88 | 2022-2025 | Rexulti |
| Alkermes, INC. | $335.44 | 2019-2023 | Aristada, Lybalvi, Vivitrol |
| Braeburn INC. | $289.55 | 2023-2025 | Brixadi |
| Allergan, INC. | $201.17 | 2019-2020 | |
| Axsome Therapeutics, INC. | $135.43 | 2023-2025 | Auvelity |
| Pfizer INC. | $129.14 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.47 | 2020-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company Ltd. | $78.75 | 2022 | |
| Exact Sciences Corporation | $47.78 | 2024-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $34.27 | 2019-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $33.56 | 2022 | |
| Lilly USA, LLC | $32.29 | 2020-2025 | Zepbound, Mounjaro |
| Biohaven Pharmaceuticals, INC. | $30.86 | 2021 | |
| Biodelivery Sciences International, INC. | $29.60 | 2019-2021 | |
| Hologic Sales and Service, LLC | $22.14 | 2023 | Aptima |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Titan Pharmaceuticals, INC. | $16.84 | 2020 | |
| Neos Therapeutics, Lp | $15.01 | 2025 | Adzenys Xr-Odt |
| Pear Therapeutics (US), INC. | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristopher Patnugot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.